Safety and immunogenicity of combined dna-polyethylenimine and oral bacterial idiotypic vaccine for patients with b-cell non-hodgkin lymphoma: a pilot study

HIGHLIGHTS

• who: Alexander Meleshko and colleagues from the Department of Clinical and Molecular Cancer Sciences, ISMIB, University of Liverpool, Liverpool, UK have published the research work: Safety and Immunogenicity of Combined DNA-Polyethylenimine and Oral Bacterial Idiotypic Vaccine for Patients with B-Cell Non-Hodgkin Lymphoma: A Pilot Study, in the Journal: Cancers 2022, x of /2022/
• what: The authors report in brief the results of a phase I non-randomized study of idiotypic vaccination in patients with B-cell non-Hodgkin's lymphoma (ISRCTN31090206). The study objectives were to examine safety and tolerability, as well . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.